<DOC>
	<DOCNO>NCT02032563</DOCNO>
	<brief_summary>We verify IV inject ICG may colour breast tumor axillary lymph node neoadjuvant therapy ( chemo- hormonotherapy )</brief_summary>
	<brief_title>Study ICG Distribution Breast Tumours Axillary Lymph Nodes Patients After Neoadjuvant Therapy</brief_title>
	<detailed_description>In operating room : ICG 0.25 mg/kg give iv injection least 20 minute begin operation . Optionally , dynamic NIR imaging center tumor bearing breast acquire 15 minute injection ( comparison standard know fluorescence intensity ) . Optionally case tumorectomy , peroperative `` vivo '' image surgical dissection acquire . The tumour and/or mammary piece ( axillary piece ) dissection directly image `` ex vivo '' use PDE camera ( comparison standard know fluorescence intensity ) . In Laboratory Pathology : The fresh mammary piece process usual , `` gross-thick '' section image use PDE fluorescent area define ( later analyze comparison standard know fluorescence intensity ) . After fixation , tumoral tissue well - identify - non tumoral fluorescent focus thereafter process `` usual '' . All slide obtain analyzed use NIR fluorescent microscope presence detectable ICG ICG-positive tissue compartment ( vascular space , interstitial space , normal and/or tumoral cell , macrophagesâ€¦ ) determine . If fluorescent focus identify level axillary piece , isolate analyze like lymph node . Using NIR fluorescent microscope , isolate macroscopically fluorescent structure analyze ( lymph node ? Other ? ) . Additionally , metastatic lymph node also control microscopic fluorescence .</detailed_description>
	<criteria>Patients histopathological diagnosis mammary cancer receive neoadjuvant therapy candidate , either tumorectomy , mastectomy complete axillary node dissection , Informed consent form sign . Diagnosis mammary cancer establish , either tumorectomy , `` gross '' biopsy , Age less than18 year old . Inability give inform consent . History allergy hypersensitivity investigational product ( active substance ingredient ) , iodine shellfish . Apparent hyperthyroidism , autonomous thyroid adenoma , unifocal , multifocal disseminate autonomy thyroid gland . Documented coronary disease . Advanced renal impairment ( creatinine &gt; 1,5mg/dl ) . During 2 week enrolment , concurrent medication reduces increase extinction ICG ( i.e . anticonvulsant , haloperidol Heparin ) . Pregnancy , breastfeed</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>neoadjuvant therapy</keyword>
</DOC>